Archive for the ‘generic drugs’ Category
The European Commission has asked a series of original drug manufacturers about the agreements signed in 2010 with patents to generic manufacturers in order to verify whether these agreements are delaying the arrival of generics to the market, which could violate law EU competition.
“Patent agreements are an area of special concern because they may delay the market entry of generic drugs,” said Vice President of the Commission responsible for competition, Joaquin Alumina said in a statement. The research will, continued to verify if the problem deals have continued their downward trend last year and to detect cases that require further examination.
The EU executive has not identified the companies to which addressed its request for information.
Research on competition in the pharmaceutical sector by the Committee for 2009 revealed that some patent agreements harm consumers because they delay entry into the market for cheaper generic.
In 2010, Brussels conducted a review, which showed that the number of problematic agreements had fallen to 10% of the total from 22% on average between 2000-2008. The amount of money in the agreements between drug manufacturers and generic manufacturer’s originals also fell more than 200 million to less than 1 million.
EU executive’s view, this shows that it has increased awareness among the industry about the type of agreements that may be investigated for cause competition concerns. In addition, is also good news for consumers?
Brussels examine copies of the agreements that they send pharmaceutical companies in the coming weeks and publish a statistical report for the first half of 2011. If you encounter specific problems in a covenant, could launch a thorough investigation.